

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

**VOLUNTARY ANNOUNCEMENT
RESEARCH AND DEVELOPMENT UPDATE
PRIMARY CLINICAL RESPONSE ON
Carteyva® (RELMACABTAGENE AUTOLEUCEL INJECTION) AT
THE 63RD AMERICAN SOCIETY OF
HEMATOLOGY ANNUAL MEETING**

JW (Cayman) Therapeutics Co. Ltd (the “**Company**” or “**JW Therapeutics**”, together with its subsidiaries, the “**Group**”), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the primary clinical response on Carteyva® (relmacabtagene autoleucel injection) in adults with relapsed or refractory (r/r) follicular lymphoma (FL) in China, at the 63rd American Society of Hematology Annual Meeting today.

As of the data cut-off of September 10, 2021, 28 patients were treated with Carteyva® with at least three months of follow-up. Of 27 efficacy evaluable patients, as assessed by the investigator, best overall response rate (ORR) was 100% (27 out of 27) and best complete response rate (CRR) was 92.6% (25 out of 27). With a median follow-up of 8.84 months, the median duration of response (DOR), progression-free survival (PFS) and overall survival (OS) were not reached. In 28 patients who received Carteyva®, any grade and severe (grade≥3) cytokine release syndrome (CRS) were 42.9% and 0%, respectively, and any grade and severe (grade≥3) neurotoxicity (NT) were 17.9% and 3.6%, respectively.

Dr. Mark J. Gilbert, Chief Medical Officer of JW Therapeutics, commented: “Most patients with r/r FL remain incurable and eventually relapse or progress. Results from this pivotal study provide evidence that Carteyva® can result in high tumor remission rates and a manageable toxicity profile in r/r FL patient. Encouraged by these findings, we are looking forward to expanding the indication of Carteyva® into r/r FL and hopefully benefiting more patients soon.”

About Relmacabtagene Autoleucel Injection (Trade name: Carteyva®)

Relmacabtagene Autoleucel Injection (abbreviated as relma-cel, trade name: Carteyva®) is an autologous anti-CD19 chimeric antigen receptor T (“**CAR-T**”) cell immunotherapy product that was independently developed by JW Therapeutics based on a CAR-T cell process platform of Juno Therapeutics (a Bristol Myers Squibb company). The first product of JW Therapeutics, relma-cel was approved by the China National Medical Products Administration in September 2021 for the treatment of adult patients with r/r large B-cell lymphoma after two or more lines of systemic therapy, making it the first CAR-T product approved as a Category 1 biologics product in China. Currently, it is the only CAR-T product in China that has been simultaneously included in the National Significant New Drug Development Program, granted priority review and breakthrough therapy designations.

About JW Therapeutics

JW Therapeutics is an independent innovative biotechnology company focusing on the developing, manufacturing and independent, commercializing cell immunotherapy products. Co-founded by Juno Therapeutics (a Bristol Myers Squibb company) and WuXi AppTec in 2016, JW Therapeutics is committed to becoming an innovation leader in cell immunotherapy. The Company has built a top world-class platform for technology and product development in cell immunotherapy, as well as a promising product pipeline covering both hematologic malignancies and solid tumors, to bring hope of cure for Chinese and global patients, and to lead the healthy and standardized development of China’s cell immunotherapy industry.

For more information, please visit www.jwtherapeutics.com.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: JW Therapeutics cannot guarantee that it will be able to develop, or ultimately market relma-cel successfully. Shareholders and potential investors of JW Therapeutics are advised to exercise due care when dealing in the shares of JW Therapeutics.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Yiping James Li
Chairman

Shanghai, PRC, December 12, 2021

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yiping James Li as Chairman and executive Director, Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Chi Shing Li, Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.

* For identification purpose only